Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a single submucosal injection trial of STNM01 in ulcerative colitis
2012-004768-23Phase 2Completed
- Sponsor
- Stelic Institute & Co.
- Start
- Feb 2013
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of stnm01 in autoimmune colitis, sponsored by Stelic Institute & Co. Primary endpoint: Primary mucosal healing efficacy. Started Feb 2013; status: completed.
02
Drugs
stnm01
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2012-004768-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004768-23.